ES2161693T3 - Morfogenesis inducida por proteinas. - Google Patents

Morfogenesis inducida por proteinas.

Info

Publication number
ES2161693T3
ES2161693T3 ES92910260T ES92910260T ES2161693T3 ES 2161693 T3 ES2161693 T3 ES 2161693T3 ES 92910260 T ES92910260 T ES 92910260T ES 92910260 T ES92910260 T ES 92910260T ES 2161693 T3 ES2161693 T3 ES 2161693T3
Authority
ES
Spain
Prior art keywords
proteins
methods
fabrics
morphogenesis
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910260T
Other languages
English (en)
Inventor
Charles M Cohen
Thangavel Kuberasampath
Roy H L Pang
Hermann Oppermann
David C Rueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24677555&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2161693(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ES2161693T3 publication Critical patent/ES2161693T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/0231—Chemically defined matrices, e.g. alginate gels, for immobilising, holding or storing cells, tissue or organs for preservation purposes; Chemically altering or fixing cells, tissue or organs, e.g. by cross-linking, for preservation purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A61K6/54—Filling; Sealing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

SE PRESENTAN 1) DATOS DE LA SECUENCIA DEL AMINOACIDO, CARACTERISTICAS ESTRUCTURALES, HOMOLOGIAS Y OTROS DATOS DIFERENTES QUE CARACTERIZAN PROTEINAS MORFOGENICAS, 2) METODOS PARA PRODUCIR ESTAS PROTEINAS A PARTIR DE FUENTES NATURALES Y RECOMBINANTES Y A PARTIR DE CONSTRUCCIONES SINTETICAS, 3) DISPOSITIVOS MORFOGENICOS QUE COMPRENDEN ESTAS PROTEINAS MORFOGENICAS Y UNA MATRIZ ESPECIFICA PARA TEJIDOS ADECUADAMENTE MODIFICADA Y 4) METODOS PARA INDUCIR EL CRECIMIENTO DE TEJIDOS NO-CONDROGENICOS EN LOS MAMIFEROS.
ES92910260T 1991-03-11 1992-03-11 Morfogenesis inducida por proteinas. Expired - Lifetime ES2161693T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66727491A 1991-03-11 1991-03-11

Publications (1)

Publication Number Publication Date
ES2161693T3 true ES2161693T3 (es) 2001-12-16

Family

ID=24677555

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910260T Expired - Lifetime ES2161693T3 (es) 1991-03-11 1992-03-11 Morfogenesis inducida por proteinas.

Country Status (9)

Country Link
EP (1) EP0575555B1 (es)
JP (1) JP3627985B2 (es)
AT (1) ATE203166T1 (es)
AU (1) AU660019B2 (es)
DE (1) DE69231946T2 (es)
DK (1) DK0575555T3 (es)
ES (1) ES2161693T3 (es)
GR (1) GR3036950T3 (es)
WO (1) WO1992015323A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
US6090776A (en) * 1991-03-11 2000-07-18 Creative Bio Molecules, Inc. Morphogen treatment of organ implants
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6723698B2 (en) 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US5739107A (en) 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6194376B1 (en) 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
CA2104678C (en) 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US5656593A (en) * 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
JP3616089B2 (ja) * 1991-08-30 2005-02-02 キュリス インコーポレイテッド 形態形成誘導蛋白のスクリーニング方法
EP0601135B1 (en) * 1991-08-30 2005-11-02 Curis, Inc. Osteogenic proteins in the treatment of metabolic bone diseases
ATE192931T1 (de) * 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
US5610021A (en) * 1992-02-21 1997-03-11 Creative Biomolecules, Inc. Compositions and methods for identification and use of soluble complex forms of osteogenic proteins
JP4344012B2 (ja) * 1992-07-31 2009-10-14 ストライカー・コーポレーション 組織形成因子誘導による神経の再生と修復
ATE198049T1 (de) * 1992-09-15 2000-12-15 Creative Biomolecules Inc Behandlung von magen- und darmgeschwüren mit morphogenen
JPH08501779A (ja) * 1992-09-15 1996-02-27 クリエイティブ バイオモレキュルズ，インコーポレイテッド モルフォゲン誘導歯周組織再生
ATE162078T1 (de) 1992-09-16 1998-01-15 Creative Biomolecules Inc Morphogeninduzierte regenerierung der leber
AU681362B2 (en) * 1992-11-03 1997-08-28 Stryker Corporation OP-3-induced morphogenesis
AU682176B2 (en) * 1993-03-04 1997-09-25 Stryker Corporation Method and compositions for recombinant osteogenic protein production
ES2265146T3 (es) * 1993-08-26 2007-02-01 Genetics Institute, Llc Proteinas morfogeneticas oseas humanas para uso en regeneracion nerviosa.
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5906827A (en) † 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
JPH11501029A (ja) * 1995-03-01 1999-01-26 クリエイティブ バイオモレキュールズ，インコーポレイテッド モルフォゲン誘導性ぞうげ質再生
US6013483A (en) * 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
WO1997034618A1 (en) 1996-03-22 1997-09-25 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
US6524802B1 (en) * 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5928940A (en) * 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
CA2289123A1 (en) 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
AU742663B2 (en) * 1997-05-30 2002-01-10 Stryker Corporation Methods for evaluating tissue morphogenesis and activity
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
JP4892131B2 (ja) † 1998-11-13 2012-03-07 ストライカー コーポレイション 癌の症状を緩和する方法
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
AU3667100A (en) * 1999-04-23 2000-11-10 Sulzer Orthopedics Ltd Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
US8546334B2 (en) 2001-11-19 2013-10-01 Scil Technology Gmbh Device having osteoinductive and osteoconductive properties
DK1572950T3 (da) 2002-06-17 2013-02-04 Thrasos Inc Enkeltdomæne TDF-relaterede forbindelser og analoger deraf
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
AU2003253049A1 (en) 2002-09-10 2004-04-30 Scil Technology Gmbh Metal implant coated under reduced oxygen concentration with osteoinductive protein
CA2558395C (en) 2004-03-10 2011-11-29 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
EP1773871B1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
DK2497780T3 (en) 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
ES2474194T3 (es) 2008-02-13 2014-07-08 Keith Hruska PMO-7 para su uso en el tratamiento de la hiperplasia de la neo�ntima
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362367B1 (en) * 1988-04-08 1996-02-28 Stryker Corporation Osteogenic devices
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US4965890A (en) * 1989-06-05 1990-10-30 Fischer Morgan F Spring hinge assembly for toilet seats
ATE167486T1 (de) * 1989-10-17 1998-07-15 Stryker Corp Osteogene vorrichtungen
US5645591A (en) * 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix

Also Published As

Publication number Publication date
EP0575555B1 (en) 2001-07-18
EP0575555A4 (en) 1994-11-02
JPH06506360A (ja) 1994-07-21
AU1754392A (en) 1992-10-06
AU660019B2 (en) 1995-06-08
ATE203166T1 (de) 2001-08-15
JP3627985B2 (ja) 2005-03-09
GR3036950T3 (en) 2002-01-31
DE69231946T2 (de) 2002-04-04
DE69231946D1 (de) 2001-08-23
EP0575555A1 (en) 1993-12-29
WO1992015323A1 (en) 1992-09-17
DK0575555T3 (da) 2001-11-05

Similar Documents

Publication Publication Date Title
ES2161693T3 (es) Morfogenesis inducida por proteinas.
DK0642334T3 (da) Farmaceutiske og andre doseringsformer
AR008680A1 (es) Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion
ES2088675T3 (es) Un metodo para unir articulos y un par de articulos sujetos por el metodo.
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
DK0643767T3 (da) Osteogene peptider
MX174258B (es) Un procedimiento para corregir y optimizar la composicion de una alimentacion
BG46600A3 (en) Method for preparing derivatives of dihydrobenzofuran and of chromancarboxamides
DE69429365D1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
DE69018926D1 (de) Vakzine gegen Bordetella.
ES2162954T3 (es) Procedimiento para la produccion de derivados de purina.
BG41137A3 (en) Method for preparing dna transfer vector for maintenance and replication of desoxynucleotide sequence coding human preproinsuline
ES2077674T3 (es) Aumento de la produccion de proteinas en animales.
ES2039460T3 (es) Un procedimiento para producir una solucion inyectable de glicosido de antraciclina.
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
MX9206135A (es) Metodos
DE69206997D1 (de) Vorrichtung zur befestigung von zwei oder mehreren seismischen energiequellen an relativ fixierte positionen
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
ES2026664T3 (es) Procedimiento para la preparacion de n(diclorofosforil) triclorofosfaceno.
JPS6436329A (en) Character string registration retriever
HRPK920279B1 (en) Masterbatch for pvc mass dyeing
DE69300409D1 (de) Pharmazeutische Zusammensetzung mit antiviraler und antibakterieller Wirkung.
CO5261602A1 (es) Composicion y metodos para regular el metabolismo de la nicotina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 575555

Country of ref document: ES